JP2013527173A5 - - Google Patents

Download PDF

Info

Publication number
JP2013527173A5
JP2013527173A5 JP2013509262A JP2013509262A JP2013527173A5 JP 2013527173 A5 JP2013527173 A5 JP 2013527173A5 JP 2013509262 A JP2013509262 A JP 2013509262A JP 2013509262 A JP2013509262 A JP 2013509262A JP 2013527173 A5 JP2013527173 A5 JP 2013527173A5
Authority
JP
Japan
Prior art keywords
methyl
pyridinyl
oxo
dihydro
pyridine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013509262A
Other languages
English (en)
Japanese (ja)
Other versions
JP5889875B2 (ja
JP2013527173A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/035344 external-priority patent/WO2012005805A1/en
Publication of JP2013527173A publication Critical patent/JP2013527173A/ja
Publication of JP2013527173A5 publication Critical patent/JP2013527173A5/ja
Application granted granted Critical
Publication of JP5889875B2 publication Critical patent/JP5889875B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013509262A 2010-05-07 2011-05-05 アザインダゾール Expired - Fee Related JP5889875B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US33231410P 2010-05-07 2010-05-07
US61/332,314 2010-05-07
PCT/US2011/035344 WO2012005805A1 (en) 2010-05-07 2011-05-05 Azaindazoles

Publications (3)

Publication Number Publication Date
JP2013527173A JP2013527173A (ja) 2013-06-27
JP2013527173A5 true JP2013527173A5 (enExample) 2014-06-26
JP5889875B2 JP5889875B2 (ja) 2016-03-22

Family

ID=45441481

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013509262A Expired - Fee Related JP5889875B2 (ja) 2010-05-07 2011-05-05 アザインダゾール

Country Status (5)

Country Link
US (1) US8637509B2 (enExample)
EP (1) EP2566479B1 (enExample)
JP (1) JP5889875B2 (enExample)
ES (1) ES2528269T3 (enExample)
WO (1) WO2012005805A1 (enExample)

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2094836B1 (en) 2006-11-15 2016-06-08 Massachusetts Eye & Ear Infirmary Generation of inner ear cells
EA023788B1 (ru) 2010-05-07 2016-07-29 ГЛЭКСОСМИТКЛАЙН ЭлЭлСи Производные индола и фармацевтические композиции на их основе
JP5864546B2 (ja) 2010-05-07 2016-02-17 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーGlaxoSmithKline LLC インダゾール
CA2841142C (en) 2010-06-23 2020-12-15 Ryan D. Morin Biomarkers for non-hodgkin lymphomas and uses thereof
US9175331B2 (en) 2010-09-10 2015-11-03 Epizyme, Inc. Inhibitors of human EZH2, and methods of use thereof
BR112013005806B1 (pt) 2010-09-10 2022-05-10 Epizyme, Inc Métodos para detectar se um indivíduo é um candidato para o tratamento com ou responsivo a um inibidor de ezh2 e usos terapêuticos do dito inibidor de ezh2
JP5908493B2 (ja) 2010-12-01 2016-04-26 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーGlaxoSmithKline LLC インドール
EP3323820B1 (en) 2011-02-28 2023-05-10 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
TW201733984A (zh) 2011-04-13 2017-10-01 雅酶股份有限公司 經取代之苯化合物
AU2013203641B2 (en) * 2011-04-13 2014-08-21 Epizyme, Inc. Aryl-or heteroaryl-substituted benzene compounds
JO3438B1 (ar) 2011-04-13 2019-10-20 Epizyme Inc مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
WO2013039988A1 (en) * 2011-09-13 2013-03-21 Glax0Smithkline Llc Azaindazoles
CA2854447A1 (en) 2011-11-04 2013-05-10 Glaxosmithkline Intellectual Property (No.2) Limited Method of treatment
US9206128B2 (en) 2011-11-18 2015-12-08 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
WO2013075084A1 (en) 2011-11-18 2013-05-23 Constellation Pharmaceuticals Modulators of methyl modifying enzymes, compositions and uses thereof
WO2013120104A2 (en) 2012-02-10 2013-08-15 Constellation Pharmaceuticals Modulators of methyl modifying enzymes, compositions and uses thereof
KR102587175B1 (ko) 2012-03-12 2023-10-06 에피자임, 인코포레이티드 인간 ezh2의 억제제 및 이의 사용 방법
US9932317B2 (en) 2012-03-19 2018-04-03 Imperial Innovations Limited Quinazoline compounds and their use in therapy
IL296199B2 (en) 2012-04-13 2024-12-01 Eisai R&D Man Co Ltd Salt form of a human hi stone methyltransf erase ezh2 inhibitor
US9562041B2 (en) 2012-05-16 2017-02-07 Glaxosmithkline Llc Enhancer of zeste homolog 2 inhibitors
HK1211875A1 (en) 2012-09-07 2016-06-03 Massachusetts Eye & Ear Infirmary Treating hearing loss
CA2884848C (en) * 2012-09-28 2017-08-22 Pfizer Inc. Benzamide and heterobenzamide compounds
AU2013331380B2 (en) 2012-10-15 2018-03-22 Epizyme, Inc. Substituted benzene compounds
CA2887243C (en) 2012-10-15 2024-04-09 Epizyme, Inc. Methods of treating cancer
WO2014100665A1 (en) 2012-12-21 2014-06-26 Epizyme, Inc. 1,4-pyridone bicyclic heteroaryl compounds
UA111305C2 (uk) 2012-12-21 2016-04-11 Пфайзер Інк. Конденсовані лактами арилу та гетероарилу
US9365527B2 (en) 2013-03-14 2016-06-14 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
WO2014144659A1 (en) 2013-03-14 2014-09-18 Epizyme, Inc. Pyrazole derivatives as prmt1 inhibitors and uses thereof
AU2014260433A1 (en) 2013-03-14 2015-09-10 Epizyme, Inc. Pyrazole derivatives as arginine methyltransferase inhibitors and uses thereof
WO2014153235A2 (en) 2013-03-14 2014-09-25 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
JP2016518336A (ja) 2013-03-14 2016-06-23 エピザイム,インコーポレイティド Prmt1阻害剤としてのピラゾール誘導体およびその使用
US9447079B2 (en) 2013-03-14 2016-09-20 Epizyme, Inc. PRMT1 inhibitors and uses thereof
HRP20202008T1 (hr) 2013-03-14 2021-02-19 Epizyme, Inc. Inhibitori arginin-metiltransferaze i njihove uporabe
WO2014153208A1 (en) 2013-03-14 2014-09-25 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
US9120757B2 (en) 2013-03-14 2015-09-01 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
HK1220916A1 (zh) 2013-03-14 2017-05-19 基因泰克公司 治疗癌症和预防癌症药物抗性的方法
US9133189B2 (en) 2013-03-14 2015-09-15 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
US9745305B2 (en) 2013-03-15 2017-08-29 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
US9505745B2 (en) 2013-04-30 2016-11-29 Glaxosmithkline Intellectual Property (No. 2) Limited Enhancer of zeste homolog 2 inhibitors
ES2640386T3 (es) 2013-07-10 2017-11-02 Glaxosmithkline Intellectual Property (No. 2) Limited Potenciador de inhibidores del homólogo Zeste 2
US9624205B2 (en) * 2013-07-19 2017-04-18 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
EP3033334A1 (en) 2013-08-15 2016-06-22 Constellation Pharmaceuticals, Inc. Indole derivatives as modulators of methyl modifying enzymes, compositions and uses thereof
AU2014337300B2 (en) 2013-10-16 2019-01-03 Eisai R&D Management Co., Ltd. Hydrochloride salt form for EZH2 inhibition
WO2015168149A2 (en) 2014-04-28 2015-11-05 Massachusetts Eye & Ear Infirmary Sensorineural hair cell differentiation
CN105017221B (zh) * 2014-04-30 2019-05-28 中国医学科学院药物研究所 苯并咪唑衍生物及其制法和药物组合物与用途
AP2016009605A0 (en) 2014-06-17 2016-12-31 Pfizer Substituted dihydroisoquinolinone compounds
WO2016022776A2 (en) 2014-08-06 2016-02-11 Massachusetts Eye And Ear Infirmary Increasing atoh1 life to drive sensorineural hair cell differentiantion
KR20170081213A (ko) 2014-11-06 2017-07-11 다나-파버 캔서 인스티튜트 인크. Ezh2 억제제 및 그의 용도
CA2966336A1 (en) * 2014-11-06 2016-05-12 Dana-Farber Cancer Institute, Inc. Use of compositions modulating chromatin structure for graft versus host disease (gvhd)
AR102767A1 (es) 2014-12-05 2017-03-22 Lilly Co Eli Inhibidores de ezh2
WO2016102493A1 (en) * 2014-12-22 2016-06-30 Bayer Pharma Aktiengesellschaft Imidazopyridine ezh2 inhibitors
EP3236962A2 (en) 2014-12-23 2017-11-01 University of Copenhagen Treatment of cancer by inhibiting ezh2 activity
WO2016164463A1 (en) 2015-04-07 2016-10-13 The General Hospital Corporation Methods for reactivating genes on the inactive x chromosome
HK1256604A1 (zh) * 2015-08-03 2019-09-27 Constellation Pharmaceuticals, Inc. Ezh2抑制剂和调节性t细胞功能的调制
MX2018002344A (es) 2015-08-24 2018-07-06 Epizyme Inc Metodo para tratar el cancer.
TW201718598A (zh) 2015-08-27 2017-06-01 美國禮來大藥廠 Ezh2抑制劑
US10577350B2 (en) 2015-08-28 2020-03-03 Constellation Pharmaceuticals, Inc. Crystalline forms of (R)-N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide
DK3378859T3 (da) * 2015-11-19 2020-01-20 Jiangsu Hengrui Medicine Co Benzofuranderivater, fremgangsmåde til fremstilling deraf og anvendelse deraf i medicin
US11185536B2 (en) 2015-12-04 2021-11-30 Massachusetts Eye And Ear Infirmary Treatment of hearing loss by inhibition of casein kinase 1
CN109219439B (zh) 2016-01-29 2022-09-20 马萨诸塞眼科耳科诊所 内耳支持细胞的扩增和分化及其使用方法
JP7174408B2 (ja) 2016-02-10 2022-11-17 ウェイク・フォレスト・ユニヴァーシティ・ヘルス・サイエンシズ 肝線維症のモデル系ならびにその作製および使用方法
EP3445365A4 (en) 2016-04-22 2019-10-16 Dana-Farber Cancer Institute, Inc. EZH2 INHIBITORS AND USES THEREOF
US10987353B2 (en) 2016-05-04 2021-04-27 The Wistar Institute Of Anatomy And Biology Methods of treating cancers overexpressing CARM1 with EZH2 inhibitors and platinum-based antineoplastic drugs
CA3039059A1 (en) 2016-10-19 2018-04-26 Constellation Pharmaceuticals, Inc. Synthesis of inhibitors of ezh2
MX386586B (es) 2017-05-18 2025-03-19 Jiangsu Hengrui Medicine Co Cristal de base libre de derivados benzofurano y método de preparación.
EP3710057A1 (en) 2017-11-14 2020-09-23 Pfizer Inc Ezh2 inhibitor combination therapies
EP3823671B1 (en) 2018-07-09 2024-02-07 Fondation Asile Des Aveugles Inhibition of prc2 subunits to treat eye disorders
MA54091A (fr) 2018-10-30 2021-09-15 Repare Therapeutics Inc Composés, compositions pharmaceutiques, procédés de préparation de composés et leur utilisation en tant qu'inhibiteurs de kinase atr
CN113631541B (zh) 2019-03-25 2024-10-01 上海华汇拓医药科技有限公司 酰胺类化合物制备方法及其在医药领域的应用
EP3959521A1 (en) 2019-04-24 2022-03-02 Institut Curie Biomarkers for predicting resistance to cancer drugs
AU2020317381A1 (en) * 2019-07-22 2022-02-10 Repare Therapeutics Inc. Substituted 2-morpholinopyridine derivatives as ATR kinase inhibitors
CN119431323A (zh) 2019-07-31 2025-02-14 贝林格尔·英格海姆国际有限公司 作为cd38抑制剂的杂双环酰胺
US20220298222A1 (en) 2019-08-22 2022-09-22 Juno Therapeutics, Inc. Combination therapy of a t cell therapy and an enhancer of zeste homolog 2 (ezh2) inhibitor and related methods
CR20220547A (es) * 2020-05-01 2022-12-15 Gilead Sciences Inc Compuestos de 2,4-dioxopirimidina inhibidores de cd73
CN114315839B (zh) * 2020-09-30 2025-09-26 武汉人福创新药物研发中心有限公司 嘧啶二酮类化合物及其用途
CN113292489B (zh) * 2021-06-16 2022-08-30 泓博智源(开原)药业有限公司 二氯代二烷基烟腈的制备方法
CA3235986A1 (en) 2021-10-29 2023-05-04 Gilead Science, Inc. Cd73 compounds
US20250270191A1 (en) 2022-06-13 2025-08-28 Treeline Biosciences, Inc. Quinolone bcl6 bifunctional degraders
EP4536658A1 (en) 2022-06-13 2025-04-16 Treeline Biosciences, Inc. 1,8-naphthyridin-2-one heterobifunctional bcl6 degraders

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2889526B1 (fr) * 2005-08-04 2012-02-17 Aventis Pharma Sa 7-aza-indazoles substitues, compositions les contenant, procede de fabrication et utilisation
CA2651072A1 (en) * 2006-05-01 2007-11-08 Pfizer Products Inc. Substituted 2-amino-fused heterocyclic compounds
WO2009006577A2 (en) * 2007-07-03 2009-01-08 The Regents Of The University Of Michigan Compositions and methods for inhibiting ezh2
WO2009134666A1 (en) * 2008-04-29 2009-11-05 Boehringer Ingelheim International Gmbh Indazole compounds as ccr1 receptor antagonists
US20100113415A1 (en) * 2008-05-29 2010-05-06 Rajapakse Hemaka A Epha4 rtk inhibitors for treatment of neurological and neurodegenerative disorders and cancer
EP3323820B1 (en) 2011-02-28 2023-05-10 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds

Similar Documents

Publication Publication Date Title
JP2013527173A5 (enExample)
JP2013528591A5 (enExample)
JP2013544840A5 (enExample)
JP2013525498A5 (enExample)
CA2798622A1 (en) Indoles
AU2006200437B2 (en) Substituted alkylamine derivatives and methods of use
AU2003252011B2 (en) Substituted 2-alkylamine nicotinic amide derivatives and use there of
KR101439823B1 (ko) 골수증식성 질환 및 기타 증식성 질환의 치료에 유용한 키나제 억제제
AU2016358242B2 (en) N-substituted indole derivatives as PGE2 receptor modulators
EA016028B1 (ru) Конденсированные гетероциклические производные и их применение
JP2018118992A5 (enExample)
TW200413330A (en) Compounds for the treatment of abnormal cell growth
BR112020003254A2 (pt) moduladores da piruvato quinase e uso destes
HRP20220096T1 (hr) Inhibitori lizin specifične demetilaze-1
HRP20180546T1 (hr) Supstituirani benzilindazoli za uporabu kao inhibitori bub1 kinaze za liječenje hiperproliferativnih bolesti
JP2014531465A5 (enExample)
JP2020526556A5 (enExample)
JP2015508828A5 (enExample)
ME02416B (me) Trpv4 antagonisтi
JP2016500073A5 (enExample)
AU2002248340A1 (en) Substituted alkylamine derivatives and methods of use
BRPI0721137A2 (pt) Compostos para modulação de atividade de c-fms e/ou c-kit e usos para os mesmos.
AU2007271964A1 (en) Pyrimidine derivatives as ALK-5 inhibitors
TW200536851A (en) Compounds and methods of use
JP2015501784A5 (enExample)